Trial Profile
A Pilot Study of the Effect of Sorafenib on Molecular Biomarkers in Barrett's Esophagus With High Grade Dysplasia
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Barrett's oesophagus; Oesophageal cancer
- Focus Biomarker; Pharmacodynamics
- 20 Oct 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 29 Feb 2008 New trial record.